Philogen S.p.A
Philogen S.p.A. was founded in 1996 and is listed on the Italian Stock Exchange. The company's headquarters are in Siena, Italy, and it has a subsidiary named Philochem near Zurich, Switzerland, where research activities are performed. The company's market cap as of May 2023 is $1.6B.
The company's strategy is to deliver bioactive agents to the site of disease using antibodies or small organic ligands, thus increasing the therapeutic activity and helping spare normal tissues. It has generated a strong proprietary pipeline of clinical-stage products for various indications, such as solid tumors, rheumatoid arthritis, psoriasis, and infectious diseases.
Philogen S.p.A.'s product portfolio includes Darleukin (L19-IL2), Fibromun (L19-TNF), L19-FAP (L19-FAP), Nidlegy (L19-IL2/L19-TNF), and Vesanoid (L19-RARa). Its projects include collaborations with academic institutions, such as ETH Zurich and the University of Zurich, and pharmaceutical companies, such as Pfizer, Novartis, Boehringer Ingelheim, and Servier .
Philogen is also involved in several research projects and collaborations with academic and industrial partners. For example, Philogen is part of the Horizon 2020 project PHOENIX, which aims to develop novel nanomedicines for cancer immunotherapy. Philogen also received the European Innovation Award in 2019 for its contribution to the field of biotechnology.
Philogen S.p.A. has received several awards and recognitions for its scientific excellence and innovation, such as the Swiss Technology Award in 2004 and 2010, the Prix Galien Italia in 2010 and 2018, the European Inventor Award in 2019, and the Swiss Biotech Success Stories Award in 2020.
Foundation: 1996
Headquarters: Siena, Italy
Website: https://www.philogen.com/
